Moderna and Merck report late-stage trial results for personalized mRNA melanoma vaccine combined with Keytruda
Moderna and Merck released data Thursday showing their experimental personalized mRNA cancer vaccine, given with Keytruda, reduced the risk of melanoma recurrence or death by 42% versus Keytruda alone. The results are scheduled to be presented Saturday at a European Society for Medical Oncology meeting in Madrid. The data was released early after reports it had been published online and then removed.
8
Divergence score
4 outlets covered it, splitting into 2 framing camps across 3 bias groups.
2 camps
3 bias groups
Market signalBETA
The spectrum · how 4 outlets placed this story
LeftCenterRight
CNN
Washington Times
AP News
NY Post
Supportive of action
Neutral
Dismissive
Critical
Alarmist
International angle
Widest split · the two outlets furthest apart, and who published first
Furthest apart on this story
CNN
Experimental mRNA vaccine cuts risk melanoma returns by 42%
excited, expert-quoted, notes data release wrinkle · positive
NY Post
First-of-its-kind cancer vaccine helps reduce chances of melanoma patients’ tumors returning: study
neutral
First to report
- CNNfirst
- AP News+8.9 h
- Washington Times+9.0 h
- NY Post+18.0 h
By each outlet's earliest publish time in this story. Feeds that index slowly can appear later than they printed.
The split, in one line
Both outlets lead with the 42% reduction in recurrence or death; CNN adds expert reaction and the pulled-then-released data detail, while the Washington Times sticks to the bare trial result.
How each outlet covered it
Lightly covered so far
Too few outlets to map a left-right split. Here is each take as it stands.
Sparse coverage · 2 outlets
“Experimental mRNA vaccine cuts risk melanoma returns by 42%”
“A novel mRNA cancer vaccine helps reduce the chances of melanoma patients' tumors returning”
4 tracked claims across 4 outlets
Fact ledger
All4Claimed2Corroborated2
1/4
Claimed
The results will be presented Saturday at a European Society for Medical Oncology meeting in Madrid
Corroborated
Disputed
3 more tracked claimsSign up free to see the full ledger